Description

The TMPRSS2 Knockout A-549 Cell Line is a human CRISPR/Cas9-engineered cell model in which the TMPRSS2 gene has been disrupted to eliminate functional TMPRSS2 expression. This stable knockout line is generated in A-549 cells, a human alveolar epithelial carcinoma cell line, and provides an in vitro system for investigating TMPRSS2-dependent biology in a respiratory epithelial context. Because TMPRSS2 encodes a type II transmembrane serine protease with established roles in extracellular proteolysis and virus-associated membrane fusion processes, this model is well suited for mechanistic studies of epithelial host factors relevant to pulmonary disease and infection biology.

A-549 cells are derived from human lung adenocarcinoma and exhibit type II pneumocyte-like features, making them a widely used model for lung epithelial biology. They are commonly applied to studies of alveolar barrier-associated processes, epithelial signaling, inflammatory responses, and respiratory virus host-cell interactions. In experimental settings, A-549 cells provide a tractable system for examining how epithelial differentiation state, cytokine exposure, and oncogenic context influence cell-surface signaling and pathogen susceptibility. Their relevance to pulmonary research also makes them useful for evaluating molecular determinants of infection efficiency, epithelial protease activity, and host-response programs in lung-derived cells.

TMPRSS2 functions at the plasma membrane as a cell-surface serine protease that proteolytically processes selected extracellular or membrane-proximal substrates. It is transcriptionally regulated by androgen receptor (AR) signaling and can be modulated by dihydrotestosterone, glucocorticoids, epithelial differentiation state, and inflammatory cytokine signaling. Within host-pathogen interaction pathways, TMPRSS2 interacts functionally with ACE2 and promotes proteolytic priming of the SARS-CoV-2 spike protein and influenza A virus hemagglutinin, thereby facilitating membrane fusion competence and protease-dependent viral entry. Its activity is also positioned within a broader epithelial protease network that includes HGF, the endogenous inhibitors HAI-1/SPINT1 and HAI-2/SPINT2, and parallel proteolytic factors such as FURIN and CTSL. These relationships have made TMPRSS2 highly relevant to COVID-19, influenza, respiratory viral infection, and epithelial cancer-associated biology.

In the A-549 background, TMPRSS2 loss provides a focused approach for dissecting how surface proteolysis contributes to respiratory epithelial phenotypes. This knockout can support studies comparing TMPRSS2-dependent and TMPRSS2-independent routes of viral glycoprotein activation, plasma membrane entry, and infection efficiency in lung-derived epithelial cells. It also enables investigation of how AR-regulated transcriptional programs, epithelial state, or inflammatory stimuli intersect with protease-dependent host-cell susceptibility and cell-surface signaling in a clinically relevant pulmonary model.

Applications include respiratory virus entry studies using pseudovirus infection assays, plaque or focus-forming infection assays, and membrane fusion or infectivity readouts to define the requirement for TMPRSS2 in SARS-CoV-2 S- or influenza HA-dependent entry. The model is also useful for western blotting, RT-qPCR, RNA-seq, and immunofluorescence analyses of compensatory protease networks involving ACE2, FURIN, CTSL, SPINT1, and SPINT2 following gene disruption. Additional use cases include cell-surface protein analysis, protease activity assays, co-immunoprecipitation of relevant interacting factors, and drug sensitivity studies evaluating protease inhibitors or host-targeted antiviral strategies in lung epithelial cells. Researchers may contact Ascent Research for additional technical information, product details, or related gene-edited cell models.